登录    
  
首页 > 期刊论文 > 论文摘要
单药培美曲塞二线治疗晚期非小细胞肺癌的疗效观察
         
Efficacy of single pemetrexed as a second-line treatment for patients with advanced non-small cell lung cancer

摘    要
目的:通过病例对照研究探讨太原市不同类型肺癌的危险因素。
标    签   非小细胞肺   培美曲塞   治疗结果   Carcinoma   non-small cell lung   Pemetrexed   Treatment outcome  
 
Abstract
Objective: To investigate the efficacy of pemetrexed as a second-line treatment for patients with NSCLC (advanced non-small cell lung cancer). Methods: Fifty-six patients with stages ⅢB﹣Ⅳ NSCLC, who failed in the first-line cisplatin-based chemotherapy, were enrolled in this study between January 2008 and January 2012. All the patiients received pemetrexed 500 mg/m2 on day 1 and repeated every 21 days as a second-line chemotherapy. After two cycles of chemotherapy, the clinical efficacy and the adverse effects were evaluated. The median survival time and the one-year survival rate were calculated. Results: All the patients received 2-6 cycles of the chemotherapy with a total of 178 cycles. All patients were evaluable. Of the 56 patients, no one achieved complete response, 9 (16.1%) achieved partial response, 10 (33.9%) achieved stable disease, 28 (50.0%) achieved progressive disease. The objective response rate was 16.1% (9/56). The median survival time was 8.9 months, and the one-year survival rate was 30.35%. The common adverse effects were bone marrow suppression and gastrointestinal toxicities with a light severity and could be tolerable. No treatment-related deaths occurred. Conclusion: Chemotherapy with pemetrexed as a second-line treatment for advanced NSCLC has a definite efficacy, and the adverse effects can be tolerable.

中图分类号 R734.2   DOI 10.3781/j.issn.1000-7431.2013.10.013

 
  购买该论文  中国光学期刊网论文下载说明
      


所属栏目 临床经验

基金项目

收稿日期 2013/6/20

修改稿日期 2013/7/31

网络出版日期

作者单位点击查看


引用该论文: FANG Xue-hui,WU Qian,HAN Xue-mei,REN Xin-le,BAI Xing,ZHU Bing,LI Jin-yan,YANG Yu-hua,CHEN Li. Efficacy of single pemetrexed as a second-line treatment for patients with advanced non-small cell lung cancer[J]. Tumor, 2013, 33(10): 919~921
方学辉,吴倩,韩雪梅,任欣乐,白星,朱兵,李金燕,杨玉华,陈利. 单药培美曲塞二线治疗晚期非小细胞肺癌的疗效观察[J]. 肿瘤, 2013, 33(10): 919~921


论文评价
共有人对该论文发表了看法,其中:
人认为该论文很差
人认为该论文较差
人认为该论文一般
人认为该论文较好
人认为该论文很好
分享论文
分享到新浪微博 分享到腾讯微博 分享到人人网 分享到 Google Reader 分享到百度搜藏分享到Twitter

参考文献
【1】YOICHIRO O. Chemoradiotherapy for lungcancer[J]. Expert Opion Pharmacother, 2005,6(16):2793-2804.
 
【2】周政涛, 王金万, 鲁明骞, 等. 固定剂量率输注吉西他滨联合顺铂一线治疗非小细胞肺癌的临床研究[J]. 肿瘤,2009, 29(2):168-171.
 
【3】CHATTOPADHYAY S, MORAN R G, GOLDMANI D. Pemetrexed:biochemical and cellularpharmacology, mechanisms, and clinicalapplications[J]. Mol Cancer Ther, 2007,6(2):404-417.
 
【4】李树婷, 马飞, 孙燕. 抗肿瘤代谢新药-培美曲塞[J]. 癌症进展, 2005, 3(5):471-476.
 
【5】VOGELZANG N J, RUSTHOVEN J J, SYMANOWSKI J, et al. Phase Ⅲ study of pemetrexed in combinationwith cisplatin versus cisplatin alone in patientswith malignant pleural mesothelioma[J]. J ClinOncol, 2003, 21(14):2636-2644.
 
【6】RUSTHOVEN J, EISENHAUER E, BUTTS C, et al.Multitargeted antifolate LY231514 as first-linechemotherapy for patients with advanced nonsmall-cell lung cancer:A phase Ⅱ study. NationalCancer Institute of Canada Clinical Trials Group[J].J Clin Oncol, 1999, 17:1194-1199.
 
【7】CLARKE S J, ABRATT R, GOEDHALS L, et al.PhaseⅡ trial of pemetrexed disodium (ALIMTA,LY231514) in chemotherapy-naïve patients withadvanced non-small-cell lung cancer[J]. AnnOncol, 2002, 13(5):737-741.
 
相关信息
   标题 相关频次
 化疗序贯厄洛替尼治疗二线厄洛替尼耐药晚期非小细胞肺癌的临床疗效和安全性
 5
 重组人血管内皮抑制素联合含铂方案治疗晚期非小细胞肺癌的临床观察
 5
 GRIM-19基因对肺腺癌耐药细胞株A549/DDP药物敏感性及相关基因表达的影响
 4
 H2O2氧化刺激对紫杉醇耐药和敏感肺癌细胞的不同影响
 4
 Luffin-β靶向融合免疫毒素的构建、表达及对非小细胞肺癌的抑制作用
 4
 大剂量维生素B6预防卡培他滨所致的手足综合征
 4
 非小细胞肺癌组织中血管内皮生长因子表达与树突状细胞分布的关系
 4
 高海拔地区老年非小细胞肺癌患者接受全电视胸腔镜下肺叶切除的安全性和预后分析
 4
 人肺腺癌细胞株A549和A549/DDP的比较蛋白质组学研究
 4
 上皮-间质转化和胰岛素样生长因子Ⅰ型受体在非小细胞肺癌EGFR-TKIs获得性耐药中的作用
 4
 多靶点受体酪氨酸激酶抑制剂联合化疗治疗晚期非小细胞肺癌的Meta分析
 3
 非小细胞肺癌CD44v6表达的免疫组化研究
 3
 Ⅰ~Ⅱ期鼻腔结外NK/T细胞淋巴瘤放射治疗疗效分析
 2
 2009年恶性肿瘤临床治疗新进展
 2
 34例卵巢透明细胞癌临床分析
 2
 Autotaxin在人卵巢癌基因及蛋白水平表达的研究及意义
 2
 CIK细胞治疗恶性胸腔积液的临床研究
 2
 C-myc蛋白在睾丸肿瘤中的表达及意义
 2
 cRGD-氧化铁纳米粒的构建及应用于核磁共振成像诊断中的动物研究
 2
 ICE方案挽救治疗52例复发难治性弥漫大B细胞淋巴瘤的疗效及预后因素
 2
 Mito-FLAG方案治疗难治/复发急性髓细胞白血病的临床观察
 2
 TCR-T细胞免疫疗法在实体肿瘤治疗中的研究进展
 2
 阿帕替尼联合治疗复发难治性乳腺癌:2例病例报告及文献复习
 2
 埃罗替尼与培美曲塞对人胰腺癌细胞BXPC-3及PANC-1生长的作用
 2
 癌症的远古性及其理论和实践意义
 2
 白蛋白结合型紫杉醇治疗晚期乳腺癌的临床观察
 2
 膀胱移行细胞癌中cPKCα的表达及意义
 2
 鼻咽癌患者治疗过程中血清EB病毒抗体水平动态变化与近期疗效的关系
 2
 表达FasL的肝癌细胞通过Fas/FasL诱导T淋巴细胞发生凋亡
 2
 沉默DNAJB11基因对肝癌SMMC7721细胞增殖、周期与凋亡的影响
 2

  热点专题


关于我们  |   联系我们  |   广告投放  |   《肿瘤》杂志社版权所有 《肿瘤》杂志社   © 中国 上海 2014.3
沪ICP备15036656号-2